Last reviewed · How we verify
TD-4208
TD-4208 is a small molecule that acts as a selective inhibitor of the sodium-activated potassium channel, Nav1.5.
TD-4208 is a small molecule that acts as a selective inhibitor of the sodium-activated potassium channel, Nav1.5. Used for Atrial fibrillation for stroke prevention.
At a glance
| Generic name | TD-4208 |
|---|---|
| Also known as | revefenacin, Revefenacin |
| Sponsor | Mylan Inc. |
| Drug class | Sodium-activated potassium channel inhibitor |
| Target | Nav1.5 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By inhibiting Nav1.5, TD-4208 is thought to reduce the risk of atrial fibrillation and its associated complications. This mechanism of action is based on the channel's role in the regulation of cardiac electrical activity.
Approved indications
- Atrial fibrillation for stroke prevention
Common side effects
- Nausea
- Headache
- Dizziness
Key clinical trials
- Phase 4 COPD and Suboptimal Inspiratory Flow Rate (PHASE4)
- A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- Thorough QT (TQT) Study of TD-4208 in Healthy Subjects (PHASE1)
- Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD (PHASE3)
- Pharmacokinetics of TD-4208 in Patients With Severe Renal Impairment (PHASE1)
- Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment (PHASE1)
- A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TD-4208 CI brief — competitive landscape report
- TD-4208 updates RSS · CI watch RSS
- Mylan Inc. portfolio CI